NuGenerex Global Diagnostics

NuGenerex Diagnostics, a subsidiary of Generex Biotechnology, is a medical diagnostic company specializing in rapid point-of-care (POC) testing for infectious diseases. The company utilizes its proprietary Express II and HEMA platforms to develop and manufacture affordable, high-accuracy diagnostic kits for global health challenges, including malaria, HIV, syphilis, and tuberculosis. Its lead products, such as the NGDx-Malaria PF/PV Cassette Test Kit and the Express II Syphilis Treponemal Assay, are designed for use in resource-limited settings and have received regulatory approvals in various international markets. Despite its technological advancements and commercialized portfolio, the company's status is currently affected by the 2022 Chapter 7 liquidation of its parent company, Generex Biotechnology.